The Renin-Angiotensin-Aldosterone System and Parathyroid Hormone Control: The RAAS-PARC Study
|Study Design:||Intervention Model: Single Group Assignment
Masking: Open Label
|Official Title:||The Renin-Angiotensin-Aldosterone System and Parathyroid Hormone Control: The RAAS-PARC Study|
- Parathyroid hormone, before and after, ACE inhibitor administration [ Time Frame: Initiation of study and after 1 week of ACE inhibitor administration ] [ Designated as safety issue: No ]
- Serum and urinary aldosterone measurements before and after ACE inhibitor use [ Time Frame: On initiation of the study, and after 1 week of ACE inhibitor administration ] [ Designated as safety issue: No ]
- Serum calcium before and after ACE inhibitor administration [ Time Frame: On initiation to the study and after 1 week of ACE inhibitor use ] [ Designated as safety issue: No ]
|Study Start Date:||October 2012|
|Estimated Primary Completion Date:||December 2016 (Final data collection date for primary outcome measure)|
Lisinopril - open-label, 2.5-40mg daily
At the initial visit, each subject will receive a single dose of captopril, with blood measurements before and 1-2 hours, after the dose.Drug: Lisinopril
Each subject will receive one week of lisinopril and return for repeat for blood measurements.
The RAAS-PARC study will evaluate whether angiotensin-converting enzyme inhibitors (ACEi) can lower parathyroid hormone (PTH) in normal controls and in individuals have a diagnosis of primary hyperparathyroidism.
Emerging data has implicated the renin-angiotensin-aldosterone system (RAAS) activity with increased PTH. The principal investigator, and other investigators, have previously shown that inhibiting the RAAS may lower PTH. The current study will focus on:
- Normal Physiology: Does an ACEi (which lowers angiotensin II and aldosterone) reduce PTH in normal individuals?
- Pathophysiology: Does an ACEi reduce PTH in individuals with primary hyperparathyroidism?
The results of this study may have important implications for cardiovascular and skeletal health, as both the RAAS and PTH have been implicated as mediators of these conditions.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01691781
|Contact: Anand Vaidya, MD, MMSc||617-525-8285|
|United States, Massachusetts|
|Brigham and Women's Hospital||Recruiting|
|Boston, Massachusetts, United States, 02115|
|Contact: Anand Vaidya, MD, MMSc 617-525-8285|
|Principal Investigator: Anand Vaidya, MD, MMSc|
|Principal Investigator:||Anand Vaidya, MD, MMSc||Brigham and Women's Hospital, Harvard Medical School|